Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study - PubMed
a day ago
- #meropenem
- #ECMO
- #pharmacokinetics
- Study focused on meropenem pharmacokinetics in critically ill adults on ECMO, with or without RRT.
- A two-compartment model best described meropenem pharmacokinetics, with ECMO flow rate affecting volume of distribution and creatinine clearance/RRT influencing drug clearance.
- Optimal dosing identified as 1 g every 8 hours via continuous infusion for patients with creatinine clearance of 60-130 mL/min and ECMO flow rates of 4-6 L/min.
- This regimen showed high efficacy (100% probability of achieving target concentrations) and low toxicity risk (<4% probability of exceeding toxic levels) in patients on RRT.
- The dosing regimen remained effective against higher efficacy targets in most scenarios, confirming its safety and efficacy for critically ill patients on ECMO with or without RRT.